VISITAS RECIENTES

AUTISMO TEA PDF

AUTISMO TEA PDF
TRASTORNO ESPECTRO AUTISMO y URGENCIAS PDF

We Support The Free Share of the Medical Information

Enlaces PDF por Temas

Nota Importante

Aunque pueda contener afirmaciones, datos o apuntes procedentes de instituciones o profesionales sanitarios, la información contenida en el blog EMS Solutions International está editada y elaborada por profesionales de la salud. Recomendamos al lector que cualquier duda relacionada con la salud sea consultada con un profesional del ámbito sanitario. by Dr. Ramon REYES, MD

Niveles de Alerta Antiterrorista en España. Nivel Actual 4 de 5.

Niveles de Alerta Antiterrorista en España. Nivel Actual 4 de 5.
Fuente Ministerio de Interior de España

domingo, 28 de febrero de 2021

Skin Lesion Guide - Atlas


https://i.pinimg.com/originals/25/50/0f/25500fd2737d26072060b7f27de5ce27.jpg

 Skin Lesion Guide

✔Bulla
Circumscribed collection of free fluid, >1 cm
✔Macule
Circular flat discoloration, <1 cm brown, blue, red or hypopigmented .
✔Nodule
Circular, elevated, solid lesion, >1cm
✔Patch
Circumscribed flat discoloration, >1cm
✔Pustule
Vesicle containing pus (inflammatory cells) .
✔Plaque
Superficial elevated solid flat topped lesion, >1 cm
✔Papule
Superficial solid elevated, ≤0.5 cm, color varies
✔Vesicle
Circular collection of free fluid, ≤1 cm
✔Wheal
Edematous, transitory plaque, may last few hours
✔Crust
Dried serum or exudate on skin
✔Scale
Epidermal thickening; consists of flakes or plates of compacted desquamated layers of stratum corneum
✔Fissure
Crack or split
✔Excoriation
Linear erosion
✔Erosion
Loss of epidermis (superficial); Part or all of the epidermis has been lost
✔Lichenification
Thickening of the epidermis seen with exaggeration of normal skin lines
✔Scar
Thickening; permanent fibrotic changes that occur on the skin following damage to the dermis
Photo credit: @medical_guidelines

lesions: are structural changes in the tissues cause by damage or injury Signs: any mark, wound, or abnormally is described as a lesión



Nursing Dermatology: Lesions of the Skin Cheat Sheet for NCLEX A skin lesion is a part of the skin that has an abnormal appearance compared to the skin around it. Description of Skin Lesions and Dermatologic Disorders

sábado, 27 de febrero de 2021

Este es el estado de la vacunación contra el covid-19 en Latinoamérica. MAPA en interactivo by CNN Español

 

Este es el estado de la vacunación contra el covid-19 en Latinoamérica. MAPA en interactivo by CNN Español  

https://cnnespanol.cnn.com/2021/02/27/asi-va-la-vacunacion-contra-el-coronavirus-en-america-latina/

BEST COVID PRACTICES by JOHNSON & JOHNSON FLIGHT DEPARTMENT. About operating safely during the pandemic. MATT THURBER |



JOHNSON & JOHNSON FLIGHT DEPARTMENT TALKS BEST COVID PRACTICES

Managers and medical experts share information about operating safely during the pandemic.

MATT THURBER | FEBRUARY 2021


During the National Business Aviation Association's virtual Flight Operations Conference on February 23, flight department managers and medical experts shared information about operating safely during the COVID-19 pandemic and how vaccines may help toward a return to normal operations. The “Post COVID-19: Best Practices for Crewmembers” webinar featured Brian Abrahamson, supervisor of operations and scheduling for Merck’s flight department; Jared Taylor, a fixed-wing pilot and safety manager at Johnson & Johnson; Alexander Smith, MedAire director of nursing and health screening products; and Dr. Paulo Alves, MedAire global medical director.


The key piece of advice from the experts is that with proper risk-mitigation, flying can continue during a pandemic, but planning is essential and even with regular testing, it is still necessary to adopt best practices for mask-wearing, social distancing, hand-washing, and cleaning.


For the Johnson & Johnson flight department, which operates three fleet types (Gulfstream G550s and G650s and a Leonardo AW139 helicopter), an initial step was to consult with the company’s own medical experts and peers in other flight departments. One of the first issues was deciding whether pilots should wear masks on the flight deck. Although Taylor found in looking at other flight departments that most pilots were not wearing masks, his company’s risk assessment found that masks should be worn. The principal safety risk is the additional time needed to remove a medical mask and put on an oxygen mask in case of a rapid decompression, he explained. However, he added, “Our medical department told us we were at much greater risk by not wearing a mask. We decided that a mask was the best solution.”


MedAire’s Dr. Alves underscored that risk assessment, based on his own research into the rarity of rapid decompression events. “I’m not downplaying the potential threat,” he said. But the risk is low compared with the more immediate threat of COVID-19 infection. “If at all possible, wearing a mask is not a bad idea,” he said.


Taylor worked with Johnson & Johnson's training manager, assistant chief pilot, and standards manager to tackle the myriad problems caused by the pandemic. To start, crews were created for each airplane, and pilots were assigned to one type only. This minimized cross-contamination between pilots but also simplified the currency issues because pilots had to remain current in just one aircraft type.


When flying did eventually pick back up, much of it related to Johnson & Johnson’s work on a COVID-19 vaccine, the currency situation for pilots improved. But this also meant the department had to develop other risk-mitigation strategies for crew and passengers and, of course, it helped that Johnson & Johnson is a medically focused company.


The first step was to create an active COVID-19 testing program, as well as protocols for when testing isn’t available. Luckily, most of the international flying is cargo, without passengers, which helped simplify the process.


The flight department worked with the medical department and put in place a process that applies to all crew, flight department employees, and passengers. The day before a trip, everyone must take their temperature and if they have no COVID-19 symptoms, they can go to the airport. They must use a return-to-work app created by Johnson & Johnson for initial screening, and if the app gives them a green light, then they can enter the flight department facility, have their temperature taken, then get the COVID-19 test. Results are available in 22 minutes and this provides certainty about whether or not the candidate is shedding virus particles. “We can be certain of that [not shedding] for 24 hours,” Taylor said.


Each flight is assigned a primary and backup crew in case a primary member tests positive. But no one interacts until they all test negative. Everyone assigned to the flight must continue wearing a mask until they climb aboard and shut the door. Because the testing has determined that no viral shedding is happening for the next 24 hours, the pilots can then remove their masks and keep them off until reaching the 24-hour mark (although they may need to don masks when stopping for fuel at an FBO). For international trips, the flight carries a third pilot and a flight engineer. The aircraft are all regularly sanitized, including the application of an anti-microbial compound.


Generally, international trips can be flown within the 24-hour window by avoiding spending any extra time at the destination. But if it is impossible to obtain testing or the trip lasts longer than 24 hours, the pilots switch to wearing masks all the time.


Taylor understands that not all flight departments can afford such extensive COVID-19 surveillance protocols. But handling companies such as Universal Weather & Aviation and World Fuel can help, and his flight department does work with them. “They provide a lot of resources for us determining what we can do and can’t [for where they can travel],” he said. “But everything is constantly changing. You’ve got to be Googling and using every resource available.” Johnson & Johnson also uses MedAire to help with medical and security logistics.


“Rely on the basics,” he said. “Do your best to maintain social distance, wear a mask, and wipe things down. In the event we can’t get tested prior to departing, we can go to a local facility for an instant test. We still have to wear a mask in the cockpit if we do that.”

Experts Explain COVID-19 Testing

RELATED ARTICLE

EXPERTS EXPLAIN COVID-19 TESTING

Molecular tests are the most effective for detecting coronavirus, according to medical professionals.


“The capricious nature of travel restrictions makes this a challenge for everyone,” said MedAire’s Smith. It’s important to know ahead of time about restrictions at the planned destination, including crew protocols and testing requirements, but more importantly what to do in case of an emergency. “What if you have a positive case in Asia?” This could mean having to quarantine for weeks before being allowed to travel again or having to arrange for an air ambulance.


Smith recommends additional information resources such as the International Air Transport Association, government agencies, travel website Kayak, OpsGroup, and even China Airlines. “The most important thing is to have a plan before you go,” he said.


The Johnson & Johnson flight department employs an emergency response plan developed by Fireside Partners. If someone on a flight is displaying COVID symptoms, that person is isolated and masked and then placed in a closed-off area with no further contact with the crew. Passenger loads are limited to six on its large-cabin Gulfstreams, and plans are in place for where passengers can be isolated in case this happens.  


MedAire can also help flight operations set up testing programs. According to Smith, a regular surveillance program remains the best way to resume flying, “as often as you can with the best test possible. We sit down with operators and consult about what resources do you have, what is your risk profile, what can you feasibly do?”


Ultimately, he added, “The basics still apply. You’re trying to prevent onward transmission. How can I prevent moving this virus particle from A to B? The expectation is that you act like you’re infectious all the time. Getting access to testing so you can make [smart] decisions is empowering." 


Vaccinations are already helping to lower case numbers, but Smith doesn’t expect something like a “vaccine passport” to enable widespread travel. “We’ll see indirect effects of lower transmission numbers, hospitalizations, and lower death [numbers]. We’re seeing a significant decrease of cases in the U.S."


“There is evidence of both of the vaccines in the U.S. being equally efficacious,” he said. “For the two vaccines, there is a 99.5 percent chance you won’t get COVID-19 after 14 days with no symptoms. Even [the soon-to-be-approved] Johnson & Johnson vaccine is 100 percent effective at preventing hospitalization. Our message is, if you have the ability to get access to any vaccine, you should take it.”


https://www.bjtonline.com/business-jet-news/johnson-johnson-flight-department-talks-best-covid-practices

Estrategia de vacunación frente a la COVID-19 en España

 

Publicada la Actualización 4 de la Estrategia de vacunación frente a la COVID-19 en España

  • La Comisión de Salud Pública, en la que se encuentran representadas todas las comunidades autónomas y el Ministerio, ha acordado ya los siguientes grupos a vacunar con ARNm y AstraZeneca en previsión de una mayor disponibilidad de dosis de vacunas en el segundo trimestre del año
  • El documento incluye también la recomendación de cómo vacunar a las personas que ya hayan tenido la infección y destaca que no es necesaria la realización de pruebas serológicas ni antes ni después de la vacunación
  • La Actualización 4 hace también hincapié en que es imprescindible considerar el principio de solidaridad

26 de febrero de 2021.- El Ministerio de Sanidad acaba de publicar la Actualización número 4 de la “Estrategia de vacunación frente a la COVID-19 en España” ReadSpeaker Escuchar tras el acuerdo alcanzado por la Comisión de Salud Pública, en la que también se encuentran representadas todas las comunidades autónomas.

Dicha Actualización incluye como novedad respecto a la Actualización 3 ReadSpeaker Escuchar los siguientes grupos a vacunar con ARNm: personas de 70 a 79 años (grupo 5B), de 60 a 69 (grupo 5C), las de menos de 60 con condiciones de riesgo alto de COVID-19 grave (grupo 7) y de edades comprendidas entre los 56 y 59 (grupo 8). La definición de dichos grupos se ha realizado en previsión de una mayor disponibilidad de dosis de vacunas en el segundo trimestre del año.

Además, el documento especifica que con las vacunas de AstraZeneca, una vez completada la vacunación a colectivos con función esencial para la sociedad priorizados en la Actualización 3, se administrará a las personas de entre 45 y 55 años de edad (grupo 9).

Personas con infección previa

La Actualización incluye también las recomendaciones de vacunación de las personas con infección previa por coronavirus, tanto asintomáticas como sintomáticas. Tras la revisión de los estudios clínicos existentes se recomienda en los mayores de 55 años con diagnóstico de infección que han recibido la primera dosis, la inoculación de la segunda cuando estén completamente recuperadas y haya finalizado el período de aislamiento.

En las personas con menos de 55 años que hayan pasado la infección de forma sintomática o asintomática sólo se administrará una dosis de vacuna seis meses después de la infección.

Cabe destacar que no es necesaria la realización de pruebas serológicas ni antes ni después de estas vacunaciones.

La edad, principal factor de riesgo

El documento recuerda que el principal factor de riesgo de hospitalización y muerte por COVID-19 es la edad superior a los 60 años y que va aumentando a medida que la edad es mayor. Por ello, resalta que basado en los principios de necesidad y equidad, debe comenzarse a vacunar cuanto antes a las personas de mayor edad que no están institucionalizadas.

La Actualización 4 hace también hincapié en que es imprescindible considerar el principio de solidaridad para que las vacunas que tienen eficacia acreditada en los grupos de mayor edad, lleguen a estas personas teniendo en cuenta que todas las vacunas disponibles en España son seguras y eficaces.


Ministerio de Sanidad, Consumo y Bienestar Social - Gabinete de Prensa - Notas de Prensa (mscbs.gob.es)